Celgene Corporation

Rxkinetix, Inc.

Biostar, Inc.

Clovis Oncology, Inc.

Virginia Commonwealth University

Thermo Biostar Inc.

Endo Pharmaceuticals Colorado, Inc.

Inverness Medical-biostar, Inc.

Jeffrey B Etter

Mei Lai

Gregory R Bogart

Jay Thomas Backstrom

Garret R Moddel

Mark A Crosby

Diana M Maul

John Fitzgerald Traverse

William W Leong

Gary Joseph Rosenthal

Rachel M Ostroff

Jeffrey W Steaffens

Adrian C Samaniego

Joel A Drewes

John Frank Carpenter

Anthony J Tutino

James E Talmadge

Douglas Giles Johnson

Timothy C Rodell

Wren Henderson Schauer

Al Quick

Antonio M Santos

Alexandre J G G Carvalho

Christopher Murray

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Oral formulations of cytidine analogs and methods of use thereof

Isotopologues of 5-azacytidine

The present disclosure provides isotopologues of 5-azacytidine.

A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.

High dosage strength tablets of rucaparib

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for parenteral administration. Also provided are methods of preparing the compositions and methods of treating diseases and disorders using the compositions provided herein.

Pharmaceutical compositions of cytidine analogs and methods of use thereof

The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Provided is a pharmaceutical composition involving a concentrated mixture of a precipitated protein and a liquid medium and a method for manufacturing the concentrated mixture. The concentrated mixture is manufacturable by precipitation of a protein with a biocompatible polymer precipitating agent, followed by removal of sufficient liquid to concentrate the resulting mixture to the desired degree. The precipitated protein can be stored for a significant time in the concentrated mixture, such as intermediate between processing stages during manufacture operations.

High-concentration protein formulations and method of manufacture

The present invention provides novel compositions of allosteric hemoglobin modifiers which are substantially free of impurities, specifically polymeric impurities. In one embodiment, the novel compositions contain an allosteric hemoglobin modifier compound and less than 100 ppm of the polymeric impurities generated during the preparation of this compound. Included in the present invention are novel methods for preparing allosteric hemoglobin modifiers that are substantially free of polymeric impurities. Also included in the present invention are improved methods for the purification of the product formed by the method of this invention. The novel methods of purification comprise extracting the crude composition with a water immiscible or partially immiscible solvent such as methylisobutyl ketone (MIBK) to lower amounts of impurities, specifically polymeric impurities. Also included are methods to reduce impurities by recrystallization of the crude synthesized product, followed by filtration of the recrystallized product. The present invention also includes the products made by the processes of the invention and methods for analyzing compositions comprised of these products.

Compositions of allosteric hemoglobin modifiers and methods of making the same

An optical assay device for the detection of an analyte of interest in a sample comprising a support containing channels, an optically functional layer positioned on the support such that the optically functional layer and the support allow for laminar flow of the sample through layers of the device, an attachment layer positioned on the optically functional layer, and an analyte specific receptive layer positioned on the attachment layer.

Flow-through optical assay devices providing laminar flow of fluid samples, and methods of construction thereof

Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible polymer for pulmonary sustained drug release applications. Also provided are packaged products including drug-containing powder in a container that is receivable by and operable with a dry powder inhaler to produce an aerosol including dispersed drug-containing particles when the inhaler is actuated.

Particulate drug-containing products and method of manufacture

Device for mass transport assisted optical assays

A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first biocompatible polymer from being dissolved in vivo following administration to a host.

Composition for delivery of hematopoietic growth factor

Growing community of inventors

Boulder, CO, United States of America

Jeffrey B Etter